Curious about the best AI paragraph rewriter? An AI paragraph rewriter is software that uses machine learning to help you get more done — it combines speed, accuracy, and an interface that just works. Hands-on testing shows real-world results vary, so a short free trial is the smartest way to decide. Whether you are a beginner or a pro, the right AI paragraph rewriter slots into your workflow and pays for itself fast. Read on for hands-on impressions, pricing tiers, and the standout features that matter.
Israeli cybersecurity industry
The Israeli cybersecurity industry is a rapidly growing sector within Israel's technology and innovation ecosystem. Israel is internationally recognized as a powerhouse in the cybersecurity domain, with numerous cybersecurity startups, established companies, research institutions, and government initiatives. Tel Aviv itself is being ranked 7th in annual list of best global tech ecosystems, as reported by the Jerusalem Post. == History == The roots of Israel's cybersecurity industry can be traced back to the country's strong focus on national security and intelligence. The establishment of elite military units such as Unit 8200, the Israeli Intelligence Corps unit responsible for signals intelligence and code decryption, played a significant role in the development of cybersecurity expertise in the country. Many former members of Unit 8200 have gone on to establish successful cybersecurity companies or join existing organizations, bringing their unique skill sets and experience to the private sector. == Market overview == As of 2024, Israel housed more than 450 cybersecurity startups and companies. In 2023, the value of exits by Israeli tech companies reached $7.5 billion. Israel's cybersecurity industry is characterized by a high concentration of startups develop new technologies in areas such as network security, endpoint protection, data security, cloud security, and threat intelligence. In recent years, the sector has attracted significant investment from both local and international venture capital firms, as well as major technology companies such as Microsoft, Google, and IBM. Several Israeli cybersecurity companies have gained global recognition and success, with some being acquired by major corporations or conducting successful initial public offerings (IPOs). === Key Israeli cybersecurity companies === Some key Israeli cybersecurity companies include: Check Point Software Technologies CyberArk Cato Networks Radware Wiz === Financial activity === Israel’s cybersecurity sector has seen significant financial activity. As of 2023, mergers and acquisitions in the cybersecurity sector totaled $2.8 billion. In the first quarter of 2024, the sector secured $846 million in private funding. == Background == The military experience helped much. Israel's mandatory military service, combined with the expertise developed within elite units such as Unit 8200, has fostered a strong talent pool with practical experience in cybersecurity. Israel's thriving startup ecosystem, often referred to as the "Startup Nation," has fostered an environment of innovation and collaboration that has contributed to the growth of the cybersecurity industry. Israeli cybersecurity companies often collaborate with international partners, both in the private and public sectors, to share knowledge and develop joint solutions. === Government Initiatives and Support === The government also supported well through various initiatives, such as the Israel National Cyber Directorate (INCD), which works to strengthen cybersecurity defenses and promote the development of the sector. === Academic institutions === Israeli universities and research centers are involved in cybersecurity research and education, contributing to the development of new technologies and training the next generation of cybersecurity professionals. Academic Tech transfer offices in Israel also facilitate the commercialization of cybersecurity technologies. Some academic institutions with cybersecurity laboratories include: Tel Aviv University Technion Ben-Gurion University
Artificial intelligence in pharmacy
Artificial intelligence in pharmacy refers to the application of artificial intelligence (AI) techniques across pharmaceutical research and practice, including drug discovery, drug delivery, safety monitoring, clinical decision support, and pharmacy operations. Machine learning, deep learning, and natural language processing have been applied to tasks ranging from molecular design to patient adherence monitoring, with the aim of reducing development costs, improving accuracy, and personalizing treatment. Adoption has been uneven. Barriers include limited AI training among pharmacists, high infrastructure costs, and the risk of harm from models trained on unrepresentative data. Regulatory frameworks for AI-based pharmaceutical tools remain in active development across most jurisdictions. == Applications == === Drug discovery and development === Drug development is resource-intensive: bringing a single drug to market typically costs around $2.6 billion and takes 12–14 years. Machine learning algorithms have been applied to analyze molecular datasets to identify potential drug candidates, predict drug–target interactions, and optimize formulations. Artificial neural networks and generative adversarial networks have been used in drug discovery tasks including virtual screening, structure-activity relationship modeling, and de novo molecule generation. Peptides designed using AI methods have shown activity against multidrug-resistant bacteria, and transcriptomic data from human cell lines has been used to train deep learning models to classify drugs by therapeutic properties. Results in drug discovery have been mixed. AI models depend on the quality and diversity of their training data; those trained on narrow chemical libraries can fail to generalize to novel molecular scaffolds. The gap between high virtual screening hit rates and success in preclinical or clinical testing remains a persistent challenge, and the translation of computationally predicted candidates into approved drugs has been slower than early projections suggested. === Drug delivery systems === AI methods including neural networks, principal component analysis, and neuro-fuzzy logic have been applied to identifying biological targets for pharmaceuticals and analyzing genetic information relevant to drug design. Computational models can predict how a formulation will behave in biological systems, helping narrow the field before laboratory synthesis begins. Systems have been proposed that monitor patient response and adjust doses in real time based on individual physiology, with potential applications in chronic disease management. Research has also explored AI applications in targeted cancer treatments and oral vaccine delivery, areas where precise control over drug release kinetics is a design priority. === Drug safety === AI has been applied to predicting and detecting adverse drug reactions using techniques including knowledge graphs, logistic regression classifiers, and neural networks. A 2023 study developed a machine learning algorithm using knowledge graph analysis to classify known causes of adverse reactions. Natural language processing and deep learning models including long short-term memory (LSTM) networks have shown better performance than conventional methods for detecting opioid misuse, drawing on both structured data from electronic health records and unstructured sources such as clinical notes. AI-based pharmacovigilance systems can scan large volumes of electronic health records and social media for drug safety signals at a scale not feasible with manual review. Limitations include difficulty distinguishing drug-related adverse events from unrelated conditions in free-text data, and the need for validated benchmarks to measure model performance against existing safety monitoring standards. === Clinical decision support and personalized medicine === Machine learning systems trained on patient datasets can predict individual risk profiles, including potential allergies and drug–drug interactions, reducing the risk of harm in complex polypharmacy cases where the number of possible interactions exceeds what a clinician can readily assess. Personalized dosing models have been developed for drugs with narrow therapeutic windows — including anticoagulants and immunosuppressants — using patient-specific variables such as weight, renal function, and relevant genetic markers. Prospective clinical validation of these systems has lagged behind their technical development. Most published evaluations report performance on retrospective datasets, and the regulatory pathway for AI-based clinical decision support tools in pharmacy varies by jurisdiction. === Pharmacy operations and automation === Robotic and AI-driven systems have been applied to dispensing accuracy and pharmacy logistics. At the UCSF Medical Center, robotic technology produced 350,000 medication doses with no dispensing errors recorded. Robots such as TUG assist with preparing and transporting medications and laboratory samples within hospital settings. AI has also been applied to inventory management, with demand-forecasting systems predicting medicine requirements to reduce shortages and minimize waste from expired stock. In community pharmacy settings, AI tools have been used to flag potential prescription errors and alert pharmacists to drug–drug interactions before dispensing. === Medication adherence === Confirming that patients take prescribed medications as directed is a persistent challenge in healthcare. AI-enabled tools including smart pillboxes, RFID tags, ingestible sensors, and video check-ins have been applied to this problem. Smart pillboxes record when they are opened, providing real-time adherence data that can be reviewed remotely by care teams. Ingestible sensors transmit a signal after dissolution, offering direct confirmation of ingestion rather than proxy measures such as pill count or self-report. == Adoption challenges == === Barriers === Several barriers limit AI adoption in pharmacy practice. Many published evaluations report model performance on retrospective datasets rather than prospective clinical outcomes, making it difficult to assess real-world benefit. Pharmacists have reported limited AI training and knowledge, and research facilities often lack the computational infrastructure required for model development and validation. Models trained on biased or unrepresentative datasets can produce misleading results with direct patient safety consequences. === Regulatory frameworks === Regulatory frameworks for AI-based pharmaceutical tools are in active development. In the United States, the Food and Drug Administration (FDA) has issued guidance on AI and machine learning-based software as a medical device, addressing requirements for pre-market review and post-market performance monitoring. The European Medicines Agency has published discussion papers on the use of AI across the medicines development lifecycle, with particular attention to transparency in model training and validation. The absence of harmonized international standards creates compliance complexity for developers operating across multiple jurisdictions. === Ethical challenges === AI adoption raises data privacy and security concerns, including the risk of exposing sensitive patient information through data breaches. Algorithmic bias presents a related hazard: a model trained on an unrepresentative patient population may generate unsuitable treatment recommendations for patients not reflected in its training data, with potential for disparate outcomes across demographic groups. The opacity of some machine learning models, particularly deep neural networks, limits clinicians' ability to interpret or contest a recommendation, raising questions of accountability when a model-assisted decision results in patient harm. === Proposed solutions === Responses proposed in the literature include AI-focused education programs for pharmacists, increased public funding for healthcare AI research, encryption and governance frameworks for patient data, and regulatory requirements to prevent the use of biased training datasets. Greater transparency about training data provenance, model architecture, and validation methodology has also been recommended, including disclosure requirements in regulatory submissions. === Future directions === Research groups have called for tighter integration between AI systems and electronic health records to reduce healthcare costs and improve continuity of care across settings. International collaboration through shared AI frameworks and federated learning approaches has been proposed to address data scarcity in underrepresented patient populations and accelerate validation across institutions.
Torment: Tides of Numenera
Torment: Tides of Numenera is a 2017 role-playing video game developed by inXile Entertainment and published by Techland Publishing for Microsoft Windows, macOS, Linux, PlayStation 4 and Xbox One. It is a spiritual successor to 1999's Planescape: Torment. The game takes place in The Ninth World, a science fantasy campaign setting written by Monte Cook for his tabletop RPG Numenera. Torment: Tides of Numenera, like its predecessor, is primarily story-driven while placing greater emphasis on interaction with the world and characters, with combat and item accumulation taking a secondary role. The game was crowd-funded through Kickstarter in March 2013. At the campaign's conclusion, Torment: Tides of Numenera had set the record for highest-funded video game on Kickstarter with over US$4 million pledged. The release date was initially set for December 2014, but was pushed back to February 2017. == Gameplay == Torment: Tides of Numenera uses the Unity engine to display the pre-rendered 2.5D isometric perspective environments. The tabletop ruleset of Monte Cook's Numenera has been adapted to serve as the game's rule mechanic, and its Ninth World setting is where the events of Torment: Tides of Numenera take place. The player experiences the game from the point of view of the Last Castoff, a human host that was once inhabited by a powerful being, but was suddenly abandoned without memory of prior events. As with its spiritual predecessor, Planescape: Torment, the gameplay of Torment: Tides of Numenera places a large emphasis on storytelling, which unfolds through a "rich, personal narrative", and complex character interaction through the familiar dialog tree system. The player is able to select the gender of the protagonist, who will otherwise start the game as a "blank slate", and may develop his or her skills and personality from their interactions with the world. The Numenera setting provides three base character classes: Glaive (warrior), Nano (wizard) and Jack (rogue). These classes can be further customized with a number of descriptors (such as "Tough" or "Mystical") and foci, which allow the character to excel in a certain role or combat style. Instead of a classic alignment system acting as a character's ethical and moral compass, Torment: Tides of Numenera uses "Tides" to represent the reactions a person inspires in their peers. Each Tide has a specific color and embodies a number of nuanced concepts that are associated with it. The composition of Tides a character has manipulated the most determines their Legacy, which roughly describes the way they have taken in life. Different Legacies may affect what bonuses and powers certain weapons and relics provide, as well as give a character special abilities and enhance certain skills. == Synopsis == === Setting === Tides of Numenera has a science fantasy setting. In the far future (one billion years), the rise and fall of countless civilizations have left Earth in a roughly medieval state, with most of humanity living in simple settlements, surrounded by technological relics of the mysterious past. The current age is called the "Ninth World" by its scholars, who believe that eight great ages existed and were destroyed, disappeared or left the Earth for unknown reasons before the present day, leaving ruins and various oddities and artifacts behind. These artifacts are known as the "numenera" and represent what is left of the science and technology of these past civilizations. Many of them are irreparably broken, but some are still able to function in ways that are beyond the level of understanding of most humans, who believe these objects to be magical in nature. === Characters === Character complexity and dialogue depth were identified among the primary elements of the Planescape: Torment legacy to be preserved and refined by the developers of Torment: Tides of Numenera. The tormented nature of the game's protagonist, the Last Castoff, attracts other, similarly affected people. They will play a significant role in his or her story as friends and companions, or as powerful enemies. The game contains seven companions in total: Aligern, Callistege, Erritis, Matkina, Oom, Tybir, and Rhin. === Plot === The protagonist of the story, known as the Last Castoff, is the final vessel for the consciousness of an ancient man, who managed to find a way to leave his physical body and be reborn in a new one, thus achieving a kind of immortality by means of the relics. The actions of this man, known as the Changing God to some, attracted the enmity of "The Sorrow" (renamed from "The Angel of Entropy" to reduce the potential to imply a religious role), who now seeks to destroy him and his creations. The Last Castoff, being one such "creation", is also targeted by the Sorrow, and must find their master before both are undone. To do so, the protagonist must explore the Ninth World, discovering other castoffs, making friends and enemies along the way. One means of such exploration are the "Meres" – artifacts that let their user gain control over the lives of other castoffs, and experience different worlds or dimensions through them. Through these travels the Last Castoff will leave their mark on the world – their Legacy – and will find an answer to the fundamental question of the story: What does one life matter? While the overall story varies wildly depending on personal preferences and specific interactions, the central storyline follows the Last Castoff as they search for a way to defeat or escape the Sorrow. They explore Sagus Cliffs after falling from a great height into a domed structure, destroying an artifact known as a resonance chamber that is believed to be capable saving the Last Castoff from the Sorrow. Finding another castoff, Matkina, The Last uses a Mere, a repository of memory to locate the entrance to Sanctuary. Using the Mere also alters the past, allowing Matkina to be healed of her mental damage. The Last finds Sanctuary, which the Changing God created as a hiding place from the Sorrow, where the Last finds a number of castoffs who represent both sides of the Eternal War: a conflict between followers of the Changing God, and followers of the First Castoff, who believe the God is selfish and malevolent. The Sorrow breaches Sanctuary after the Last is told that the resonance chamber will "defeat" the Sorrow by destroying every castoff in existence. After escaping the Sorrow through a portal to the Bloom, an apparition appears claiming to be the actual Changing God and attempts to possess the Last by force of will. == Development == In a 2007 interview, designers Chris Avellone and Colin McComb, who had worked on Planescape: Torment, stated that although a direct sequel was not considered because the game's story was over, they were open to the idea of a similar-themed Planescape game if they could gather most of the original development team and find an "understanding set of investors". This combination was deemed infeasible at the time. Talks about creating a sequel with the help of a crowd funding platform resumed in 2012, but attempts to acquire a Planescape license from Wizards of the Coast failed. Later that year, Colin McComb joined inXile, which was at the time working on its successfully crowd funded Wasteland 2 project. The studio gained the rights to the Torment title shortly thereafter. In January 2013, inXile's CEO Brian Fargo announced that the spiritual successor to Planescape: Torment was in pre-production and would be set in the Numenera RPG universe created by Monte Cook. Cook acted as one of the designers of the Planescape setting, and Fargo saw the Numenera setting as the natural place to continue the themes of the previous Torment title. Although the connections to its predecessor will not be relatively overt, due to licensing issues, it was noted that certain traditional RPG elements are relatively hard to copyright, and some elements of Planescape: Torment may make a reappearance. Development of the game began shortly after the acquisition of the Torment license, and various inXile staff will transition over to the Numenera team as production on Wasteland 2 winds down. In late January 2013, inXile confirmed the game's title as Torment: Tides of Numenera, and announced that Planescape: Torment composer Mark Morgan would create the soundtrack. The pre-production period was initially expected to continue until October 2013. During this phase, team composition for the project was to be finalised and development would focus on production planning, game design and dialog writing. With the Wasteland 2 project facing delays in 2014, full production of Torment: Tides of Numenera was rescheduled to a later date. A Kickstarter campaign to crowd fund Torment: Tides of Numenera was launched on March 6, 2013 with a US$900,000 goal. Project director Kevin Saunders explained this choice of a funding source by stating that the traditional publisher-based funding model is flawed
Oblivion (2013 film)
Oblivion is a 2013 American epic post-apocalyptic science fiction action film produced and directed by Joseph Kosinski from a screenplay by Karl Gajdusek and Michael deBruyn, starring Tom Cruise in the main role alongside Morgan Freeman, Olga Kurylenko, Andrea Riseborough, Nikolaj Coster-Waldau, and Melissa Leo in supporting roles. Based on Kosinski's unpublished Radical Comics graphic novel of the same name, the film pays homage to 1970s sci-fi, and is a "love story" set in 2077 on an Earth desolated by an alien war; a maintenance technician on the verge of completing his mission finds a woman who survived from a space ship crash, leading him to question his purpose and discover the truth about the war. Oblivion premiered in Buenos Aires on March 26, 2013, and was released in theaters by Universal Pictures on April 19. The film grossed $286 million worldwide on a production budget of $120 million and received mixed reviews from critics. == Plot == In 2017, aliens known as Scavengers attack Earth and destroy the Moon, triggering global natural disasters. Although humanity wins the war using nuclear weapons, Earth is left uninhabitable. Sixty years later, the remnants of humanity have relocated to a colony on Saturn's moon Titan, except for Unit 49—technician Jack and his communications officer Victoria—who are scheduled to join them in two weeks. The pair oversee hydro rigs that convert seawater into fusion energy for the Tet, the last remaining human colony ship in orbit. Though Jack and Victoria are romantically involved and have had their memories erased for security reasons, Jack experiences recurring dreams of an unknown woman. He also secretly visits a hidden, verdant valley where he has built a lakeside cabin and collects relics of Earth's past. While investigating a missing drone—autonomous, highly advanced, and heavily armed machines—Jack is nearly captured by Scavengers. Later, he discovers the Scavengers are transmitting a signal into space. A NASA pod crash-lands at the signal's coordinates, carrying five humans in suspended animation, including the woman from Jack's dreams. A drone arrives and destroys four of the pods, but Jack rescues the remaining one and brings the unconscious woman to Unit 49's base. After reviving her, Jack and Victoria learn that the woman, Julia, has been in stasis aboard the Odyssey spaceship since 2017. Julia insists on recovering the ship's flight recorder. However, she and Jack are captured by Scavengers and brought to the Raven Rock Mountain Complex. Their leader, Malcolm, reveals that the Scavengers are actually surviving humans. Malcolm needs Jack to reprogram a captured drone to deliver a nuclear bomb, built from Odyssey's reactor, to the Tet. Jack refuses, so Malcolm releases him and Julia, urging him to seek the truth in the radiation zone, which is supposedly deadly and off-limits. Julia helps Jack recall that she is his wife, and fragments of his memories begin to return. When they arrive back at Unit 49, a devastated Victoria informs Sally, the Tet's mission controller, that she and Jack are no longer an "effective team." A drone activates and kills Victoria. Jack and Julia destroy the drone, but crash their aircraft inside the radiation zone. There, they encounter another version of Jack—"Jack-52"—who arrives to repair the drone. Jack subdues him, but Julia is seriously injured in the fight. Jack impersonates his clone to infiltrate Unit 52, meets Victoria-52, and steals medical supplies for Julia. They rest at his cabin. At Raven Rock, Malcolm reveals the truth: humanity lost the war, and the Tet is an alien machine intelligence harvesting Earth's resources. After the Moon's destruction, the Tet deployed thousands of clones of astronaut Jack Harper—brainwashed into obedience—to exterminate the remaining humans. Malcolm had assumed these clones were inhuman until witnessing Jack show interest in a discarded book, hinting at lingering humanity. Jack reprograms the captured drone, but it is destroyed in a surprise attack by other drones, leaving Malcolm badly wounded. Jack and Julia resolve to deliver the bomb themselves; Julia enters a stasis pod. En route, Jack listens to the Odyssey's flight recorder, which reveals the original Jack Harper and Victoria were astronauts sent to explore Titan before being confronted by the Tet. The pair were captured, but not before Jack ejected the remaining crew—including Julia—in stasis pods to protect them. Jack gains access to the Tet by claiming he is delivering Julia, as previously instructed. However, the stasis pod contains a dying Malcolm. Jack and Malcolm detonate the bomb, destroying the Tet and themselves. Julia later awakens at the cabin. Three years later, Julia lives there and it is revealed she had a daughter with Jack. A group of Raven Rock survivors arrives, alongside Jack-52, who has begun regaining fragments of his own lost identity. == Cast == Tom Cruise as Jack Harper—Tech 49, a technician who works to repair drones on Earth and questions his mission. Originally, he was the American commander of a mission en route to Titan who was captured by the Tet and cloned to fight humanity. Cruise also plays Jack Harper—Tech 52, a clone who seeks out Julia after the destruction of the Tet. Morgan Freeman as Malcolm Beech, an American veteran soldier and leader of a large community of scavengers, the human survivors of the alien Tet's attacks. Olga Kurylenko as Julia Rusakova Harper, Jack's wife and a Russian crew member on the Odyssey, who was sent back towards Earth by her husband to protect her from the initial contact with the Tet. Andrea Riseborough as Victoria "Vika" Olsen, Jack's communications partner and housemate. Originally, she was the British co-pilot of Jack's mission to Titan who was captured and cloned to assist in the Tet's war on humanity. Riseborough also plays a clone of Vika who Jack misleads to obtain medical supplies. Nikolaj Coster-Waldau as Sergeant Sykes, the main military commander of Beech's community of scavengers who is skeptical of Jack at first. Melissa Leo as the Tet, an alien artificial intelligence seeking to acquire Earth's natural resources and wipe out humanity. Leo also plays Sally, the mission director of Jack and Julia's mission to Titan; her likeness was copied by the Tet to serve as its visual and auditory representation. Zoë Bell as Kara, a soldier and member of the scavengers. == Production == === Development === Joseph Kosinski started the movie process by beginning work on a graphic novel called Oblivion featuring his story. While the completion of this would be teased to the public and the concept was used to pitch the movie, it was never finished and Kosinski claims he never intended to, stating it was "just a stage in the project [of film development]". Arvid Nelson was billed as co-writer and Radical Comics was attached as publisher. The novel was never finished; Kosinski explaining: "the partnership with Radical Comics allowed me to continue working on the story by developing a series of images and continuing to refine the story more over a period of years. Then I basically used all that development as a pitch kit to the studio. So even though we really never released it as an illustrated novel the story is being told as a film, which was always the intention." Walt Disney Pictures, which produced Kosinski's previous film Tron: Legacy (2010), acquired the Oblivion film adaptation rights from Radical Comics and Kosinski after a heated auction in August 2010. The film was a directing vehicle for Kosinski, with Barry Levine producing, and Jesse Berger executive producing. Other studios that made bids on the film were Paramount Pictures, 20th Century Fox, and Universal Pictures. Disney subsequently released the rights after realizing the PG-rated film they envisioned, in line with their family-oriented reputation, would require too many story changes. Universal, which had also bid for the original rights, then bought them from Kosinski and Radical and authorized a PG-13 film version. The film's script was originally written by Kosinski and William Monahan and underwent a first rewrite by Karl Gajdusek. When the film passed into Universal's hands, a final rewrite was done by Michael Arndt, under the pen name "Michael deBruyn". Universal was particularly appreciative of the script, saying, "It's one of the most beautiful scripts we've ever come across." The Bubble Ship operated by Cruise's main character, Jack 49, was inspired by the Bell 47 helicopter (often colloquially referred to as a "bubble cockpit" helicopter), a utilitarian 1947 vehicle with a transparent round canopy that Kosinski saw in the lobby of the Museum of Modern Art in Manhattan, and which he likened to a dragonfly. Daniel Simon, who previously worked with Kosinski as the lead vehicle designer on Tron: Legacy, was tasked with creating the Bubble Ship from this basis, incorporating elements evocative of an advanced fighter
GoodRx
GoodRx Holdings, Inc. is an American healthcare company that operates a telemedicine platform and free-to-use website and mobile app that track prescription drug prices in the United States and provide drug coupons for discounts on medications. GoodRx compares prescription drug prices at more than 75,000 pharmacies in the United States. The platform allows users to consult a doctor online and obtain a prescription for certain types of medications. == History == === Financial performance === GoodRx was founded in Santa Monica, California in 2011. GoodRx experienced substantial growth in net income in 2017 ($9 million), 2018 ($44 million), and 2019 ($66 million), but recorded a loss of $293.6 million in 2020 due to IPO-related expenses. In September 2020, GoodRx went public on the Nasdaq under the ticker symbol GDRX. The company priced its initial public offering at $33 per share, above the expected range of $24 to $28, raising more than $1.1 billion at an initial valuation of approximately $12.7 billion. In the first half of 2020, the company reported revenues of $257 million and net income of $55 million. GoodRx generated $745.4 million in revenue for the full year 2021, a 35.36% increase over 2020. During the first half of 2021, the company’s share price declined by 10.7%. The decline was attributed to increased competition in online pharmacy services and slower user growth. GoodRx reported full-year revenue of $766.6 million, with adjusted EBITDA reaching $213.5 million, exceeding guidance in the fourth quarter. GoodRx reported that 41% of prescriptions filled using its coupons were newly adherent, meaning they would not have been filled without the service. GoodRx reported a full-year 2023 revenue of $750.3 million, a decrease of 2.1% from 2022. However, its fourth-quarter revenue increased by 7% year-over-year. GoodRx achieved an Adjusted EBITDA of $217.4 million for the year and an Adjusted EBITDA Margin of 28.6%. In 2024, GoodRx achieved 6% revenue growth with $792.3 million for the full year and turned a net loss into a positive net income of $16.4 million. The company also demonstrated strong operational efficiency, with a 32.8% increase in full-year Adjusted EBITDA. In Q2 2025, GoodRx reported revenue of $203.1 million, a 1.2% increase from the previous year, and a net income of $12.8 million, a significant 92% jump, which resulted in a 6.3% net income margin. However, prescription transaction revenue declined by 3% due to a decrease in monthly active consumers, but this was offset by strong 32% growth in its Pharma Manufacturer Solutions business. GoodRx also saw a 7% decrease in subscription revenue. === Mergers and acquisitions === In 2019, GoodRx acquired HeyDoctor, a telemedicine company, to integrate virtual healthcare services into the platform. In 2021, a health video content producer, HealthiNation was acquired by GoodRx, which helped provide consumers with health information and offered pharmaceutical manufacturers new ways to reach relevant audiences. In April 2022, GoodRx acquired VitaCare Prescription Services from TherapeuticsMD to strengthen its pharma manufacturer solutions business. === Partnerships === In 2017, the company announced partnerships with major pharmaceutical companies to negotiate lower prescription drug costs. GoodRx has deep relationships with major pharmacy chains, including Walgreens, Walmart, CVS Caremark, and Publix, to allow customers to use GoodRx discounts and Gold benefits. GoodRx began its partnership with CVS Caremark in July 2023 to automatically apply coupons to insured CVS customers purchasing generic prescriptions at certain locations. In April 2024, GoodRx added Publix into its network, allowing GoodRx Gold members to use their cards at Publix Pharmacies. GoodRx partners with Pharmacy Benefit Management like Caremark, Express Scripts, and MedImpact to apply their savings directly to eligible insurance plans and members. GoodRx partners with companies like Affirm, Benefitfocus, and DoorDash to integrate their services that offer members discounts and financial flexibility for prescriptions. GoodRx also partners with organizations like the American Academy of Family Physicians Foundation to support broader access to care. In October 2022, GoodRx launched Provider Mode, which allows healthcare providers to use the app to compare costs of drugs for patients based on different payment methods and drug alternatives. In 2025, GoodRx partnered with Novo Nordisk to offer discounted cash-pay access to semaglutide products like Ozempic and Wegovy through its platform and participating pharmacies. == Products and services == GoodRx started its telemedicine service GoodRx Care in September 2019. It lets people talk to a licensed provider online for common issues and get prescriptions even if they don't have insurance. They also run condition-specific subscription plans that bundle online doctor visits, FDA-approved meds, and home delivery into one monthly payment. On the weight management side, GoodRx offers prescriptions for GLP-1 drugs like semaglutide through their telemedicine platform. This got a boost when the oral version of Wegovy became widely available in the US in early 2026. GoodRx works with drug makers like Novo Nordisk to make some medications (including semaglutide options) more affordable for people paying cash. The telemedicine part took off after GoodRx bought HeyDoctor in 2019 and brought their virtual care tools into the main platform. == Key people == The Santa Monica-based startup was founded in September 2011 by Trevor Bezdek and former Facebook executives Doug Hirsch and Scott Marlette. Marlette was one of the first 20 employees at Facebook and built Facebook's photo application. In 2005, Hirsch was the Vice President of Product at Facebook, working closely with Mark Zuckerberg. Bezdek and Hirsch served as co-chief executive officers until April 2023, when they stepped down from those roles and technology executive Scott Wagner was appointed interim chief executive officer. Bezdek became chair of the board, while Hirsch took on the role of chief mission officer. In December 2024, GoodRx announced that healthcare executive Wendy Barnes would become president and chief executive officer effective January 1, 2025. As of 2025, Barnes serves as the company’s CEO, while Trevor Bezdek and Scott Wagner serve as co-chairs of the board, and Doug Hirsch remains involved as a co-founder and senior executive. == Controversy == On February 25, 2020, Consumer Reports published an article stating that GoodRx shared user data—specifically, pseudonymized advertising ID numbers that companies use to track the behavior of web users across websites, the names of the drugs that users browsed, and the pharmacies where users sought to fill prescriptions—with Google, Facebook, and around twenty other Internet-based companies. A few days later, GoodRx released a statement saying that it had made changes to prevent user search data on medical conditions and pharmaceuticals from being shared with Facebook. In March 2020, GoodRx stopped sending data about user prescriptions to Facebook. On February 1, 2023, the Federal Trade Commission fined GoodRx US$1.5 million for violations of the Breach Notification Rule and the Federal Trade Commission Act for allegedly failing to obtain specific, informed, and unambiguous consent from users before disclosing health-related information to Facebook and Google. In November 2024, independent pharmacies filed at least three class action lawsuits against GoodRx and major pharmacy benefit managers. The cases, brought by independent pharmacies in California, Michigan, Pennsylvania, and Rhode Island, allege that GoodRx and the PBMs collaborated to suppress reimbursements for generic prescription drugs. They allege that agreements using GoodRx’s software suppressed reimbursements for generic drugs and violated the Sherman Antitrust Act. The suits claim the practices amount to price fixing which harms small pharmacies while benefiting PBMs and their affiliates. GoodRx settled both the 2023 FTC action and the 2025 class action lawsuit without admitting wrongdoing.
Stable Diffusion
Stable Diffusion is a deep learning, text-to-image model released in 2022 based on diffusion techniques. The generative artificial intelligence technology is the premier product of Stability AI and is considered to be a part of the ongoing AI boom. It is primarily used to generate detailed images conditioned on text descriptions, though it can also be applied to other tasks such as inpainting, outpainting, and generating image-to-image translations guided by a text prompt. Its development involved researchers from the CompVis Group at LMU Munich and Runway with a computational donation from Stability and training data from non-profit organizations. Stable Diffusion is a latent diffusion model, a kind of deep generative artificial neural network. Its code and model weights have been released publicly, and an optimized version can run on most consumer hardware equipped with a modest GPU with as little as 2.4 GB VRAM. This marked a departure from previous proprietary text-to-image models such as DALL-E and Midjourney which were accessible only via cloud services. == Development == Stable Diffusion originated from a project called Latent Diffusion, developed in Germany by researchers at LMU Munich in Munich and Heidelberg University. Four of the original 5 authors (Robin Rombach, Andreas Blattmann, Patrick Esser and Dominik Lorenz) later joined Stability AI and released subsequent versions of Stable Diffusion. The technical license for the model was released by the CompVis group at LMU Munich. Development was led by Patrick Esser of Runway and Robin Rombach of CompVis, who were among the researchers who had earlier invented the latent diffusion model architecture used by Stable Diffusion. Stability AI also credited EleutherAI and LAION (a German nonprofit which assembled the dataset on which Stable Diffusion was trained) as supporters of the project. == Technology == === Architecture === Diffusion models, introduced in 2015, are trained with the objective of removing successive applications of Gaussian noise on training images, which can be thought of as a sequence of denoising autoencoders. The name diffusion is from the thermodynamic diffusion, since they were first developed with inspiration from thermodynamics. Models in Stable Diffusion series before SD 3 all used a variant of diffusion models, called latent diffusion model (LDM), developed in 2021 by the CompVis (Computer Vision & Learning) group at LMU Munich. Stable Diffusion consists of 3 parts: the variational autoencoder (VAE), U-Net, and an optional text encoder. The VAE encoder compresses the image from pixel space to a smaller dimensional latent space, capturing a more fundamental semantic meaning of the image. Gaussian noise is iteratively applied to the compressed latent representation during forward diffusion. The U-Net block, composed of a ResNet backbone, denoises the output from forward diffusion backwards to obtain a latent representation. Finally, the VAE decoder generates the final image by converting the representation back into pixel space. The denoising step can be flexibly conditioned on a string of text, an image, or another modality. The encoded conditioning data is exposed to denoising U-Nets via a cross-attention mechanism. For conditioning on text, the fixed, pretrained CLIP ViT-L/14 text encoder is used to transform text prompts to an embedding space. Researchers point to increased computational efficiency for training and generation as an advantage of LDMs. With 860 million parameters in the U-Net and 123 million in the text encoder, Stable Diffusion is considered relatively lightweight by 2022 standards, and unlike other diffusion models, it can run on consumer GPUs, and even CPU-only if using the OpenVINO version of Stable Diffusion. ==== SD XL ==== The XL version uses the same LDM architecture as previous versions, except larger: larger UNet backbone, larger cross-attention context, two text encoders instead of one, and trained on multiple aspect ratios (not just the square aspect ratio like previous versions). The SD XL Refiner, released at the same time, has the same architecture as SD XL, but it was trained for adding fine details to preexisting images via text-conditional img2img. ==== SD 3.0 ==== The 3.0 version completely changes the backbone. Not a UNet, but a Rectified Flow Transformer, which implements the rectified flow method with a Transformer. The Transformer architecture used for SD 3.0 has three "tracks", for original text encoding, transformed text encoding, and image encoding (in latent space). The transformed text encoding and image encoding are mixed during each transformer block. The architecture is named "multimodal diffusion transformer (MMDiT), where the "multimodal" means that it mixes text and image encodings inside its operations. This differs from previous versions of DiT, where the text encoding affects the image encoding, but not vice versa. === Training data === Stable Diffusion was trained on pairs of images and captions taken from LAION-5B, a publicly available dataset derived from Common Crawl data scraped from the web, where 5 billion image-text pairs were classified based on language and filtered into separate datasets by resolution, a predicted likelihood of containing a watermark, and predicted "aesthetic" score (e.g. subjective visual quality). The dataset was created by LAION, a German non-profit which receives funding from Stability AI. The Stable Diffusion model was trained on three subsets of LAION-5B: laion2B-en, laion-high-resolution, and laion-aesthetics v2 5+. A third-party analysis of the model's training data identified that out of a smaller subset of 12 million images taken from the original wider dataset used, approximately 47% of the sample size of images came from 100 different domains, with Pinterest taking up 8.5% of the subset, followed by websites such as WordPress, Blogspot, Flickr, DeviantArt and Wikimedia Commons. An investigation by Bayerischer Rundfunk showed that LAION's datasets, hosted on Hugging Face, contain large amounts of private and sensitive data. === Training procedures === The model was initially trained on the laion2B-en and laion-high-resolution subsets, with the last few rounds of training done on LAION-Aesthetics v2 5+, a subset of 600 million captioned images which the LAION-Aesthetics Predictor V2 predicted that humans would, on average, give a score of at least 5 out of 10 when asked to rate how much they liked them. The LAION-Aesthetics v2 5+ subset also excluded low-resolution images and images which LAION-5B-WatermarkDetection identified as carrying a watermark with greater than 80% probability. Final rounds of training additionally dropped 10% of text conditioning to improve Classifier-Free Diffusion Guidance. The model was trained using 256 Nvidia A100 GPUs on Amazon Web Services for a total of 150,000 GPU-hours, at a cost of $600,000. === Limitations === Stable Diffusion has issues with degradation and inaccuracies in certain scenarios. Initial releases of the model were trained on a dataset that consists of 512×512 resolution images, meaning that the quality of generated images noticeably degrades when user specifications deviate from its "expected" 512×512 resolution; the version 2.0 update of the Stable Diffusion model later introduced the ability to natively generate images at 768×768 resolution. Another challenge is in generating human limbs due to poor data quality of limbs in the LAION database. The model is insufficiently trained to replicate human limbs and faces due to the lack of representative features in the database, and prompting the model to generate images of such type can confound the model. In addition to human limbs, Stable Diffusion is unable to generate legible ambigrams and some other forms of text and typography. Stable Diffusion XL (SDXL) version 1.0, released in July 2023, introduced native 1024x1024 resolution and improved generation for limbs and text. Accessibility for individual developers can also be a problem. In order to customize the model for new use cases that are not included in the dataset, such as generating anime characters ("waifu diffusion"), new data and further training are required. Fine-tuned adaptations of Stable Diffusion created through additional retraining have been used for a variety of different use-cases, from medical imaging to algorithmically generated music. However, this fine-tuning process is sensitive to the quality of new data; low resolution images or different resolutions from the original data can not only fail to learn the new task but degrade the overall performance of the model. Even when the model is additionally trained on high quality images, it is difficult for individuals to run models in consumer electronics. For example, the training process for waifu-diffusion requires a minimum 30 GB of VRAM, which exceeds the usual resource provided in such consumer GPUs as Nvidia's GeForce 30 series, w